Comparison of in vitro effects of triflusal and acetysalicylic acid on nitric oxide synthesis by human neutrophils

European Journal of Pharmacology

Volumn 343, Issue 1, 1998, Pages 57-65

  Sánchez De Miguel, Lourdes ^a   Casado, Santos ^a   Farré, Jerónimo ^a   García Durán, Margarita ^a   Rico, Luis A ^a   Montón, Mercedes ^a   Romero, José ^a   Bellver, Teresa ^a   Sierra, María P ^a   Guerra, José I ^a   Mata, Pedro ^a   Esteban, Andrés ^a   López Farré, Antonio ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

Acetylsalicylic acid; Neutrophils; Nitric oxide (NO); Platelet

Indexed keywords

2 HYDROXY 4 (TRIFLUOROMETHYL)BENZOIC ACID; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ARGININE; CITRULLINE; CYCLIC GMP; DRUG METABOLITE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; TRIFLUSAL; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DRUG EFFECT; HEART MUSCLE ISCHEMIA; HUMAN; HUMAN CELL; NEUTROPHIL; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

ASPIRIN; CYCLIC GMP; CYCLOOXYGENASE INHIBITORS; HUMANS; NEUTROPHILS; NITRIC OXIDE; PLATELET AGGREGATION INHIBITORS; SALICYLATES;

EID: 0032484950     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(97)01518-5     Document Type: Article

References (37)

1. Akaike T., Yoshida M., Miyamoto Y., Sato K., Kohno M., Sasamoto K., Miyazaki K., Veda S., Maeda H. Antagonist action of imidazolineoxyl N-oxides against endothelium-derived relaxing factor/NO through a radical reaction. Biochemistry. 32:1993;827-832.
2. Bredt D.S., Ferris C.D., Snyder S.H. Nitric oxide synthase regulatory sites. J. Biol. Chem. 267:1992;10976-10981.
3. Brüne B., Lapetina E.G. Phosphorylation of nitric oxide synthase by protein kinase A. Biochem. Biophys. Res. Commun. 181:1991;921-926.
4. Coller B.S. Antiplatelet agents in the prevention and therapy of thrombosis. Annu. Rev. Med. 43:1991;171-180.
5. De la Cruz J.P., Pavía J., García-Arnes J., Sánchez de la Cuesta F. Effects of triflusal and acetylsalicylic acid on platelet aggregation in whole blood of diabetic patients. Eur. J. Haematol. 40:1986;232-236.
6. De la Cruz J.P., Pavia J., Bellido I., González M.C., Sánchez de la Cuesta F. Platelet antiaggregatory effect of triflusal in human whole blood. Methods Find. Exp. Clin. Pharmacol. 10:1988;273-277.
7. De la Cruz J.P., Mata J.M., Sánchez de la Cuesta F. Triflusal versus aspirin on the inhibition of human platelet and vascular cyclooxigenase. Gen. Pharmac. 23:1992;297-300.
8. Di Gaetano G., Cerletti C., Dejana E., Latin R. Pharmacology of platelet inhibition of the salicylate-aspirin interaction. Circulation. 72:1985;1185-1193.
9. Francia E., Marín A., García-Rafanell J. Triflusal, an antithrombotic agent. Drugs Future. 3:1978;225-228.
10. García-Rafanell J., Ramis J., Gómez L., Forn J. Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets. Arch. Int. Pharmacodyn. Ther. 284:1986;155-165.
11. Gaspari F., Vigano G., Orisio S., Bonati M., Livio M., Remuzzi G. Aspirin prolongs bleeding time in uremia by a mechanism distinct from platelet cyclooxygenase inhibition. J. Clin. Invest. 79:1987;1788-1797.
12. Hoffmann G., Gobel B.O., Harbrecht U., Vette H., Dusing R. Platelet cAMP and cGMP in essential hypertension. Am. J. Hypertens. 5:1992;847-850.
13. Hudak J.M., Banitt E.H., Schmid J.R. Discovery and development of flecainide. Am. J. Cardiol. 53:1984;17B-20.
14. Johnson G., Tsao P.S., Lefer A.M. Cardioprotective effects of authentic nitric oxide in myocardial ischemia with reperfusion. Crit. Care Med. 19:1991;244-252.
15. Kerins D.M., Fitzgerald G.A. The current role of platelet-active drugs in ischemic heart disease. Drugs. 41:1991;665-671.
16. Lefer D.J., Nakanishi K., Johnston W.E., Vinter-Johansen J. Antineutrophil and myocardial protecting actions of a novel nitric oxide donor after acute myocardial ischemia and reperfusion in dogs. Circulation. 88:1993;2337-2350.
17. Lewis H.D., Davis J.W., Archibald D.G., Phil M., Steinke W.E., Smitherman T.C., Doherty J.E. III, Schnaper H.W., LeWinter M.M., Linares E., Pouget J.M., Sabharwal S.C., Chesler E., DeMots H. Protective effects of aspirin against acute myocardial infarction and death in unstable angina. N. Engl. J. Med. 309:1983;396-405.
18. López-Farré A., Riesco A., Espinosa G., Cernadas M.R., Álvarez V., Montón M., Rivas F., Gallego M.J., Egido J., Casado S., Caramelo C. Effect of endothelin-1 on neutrophil adhesion to endothelial cells and perfused heart. Circulation. 88:1993;1166-1171.
19. López-Farré A., Alberola M.L., Esteban A., Millás I., Riesco A., Montón M., Sánchez L., Casado S., Caramelo C. Regulation of platelet (PLT) aggregation by neutrophils (PMN): Role of aspirin (ASA), arachidonic acid and endothelin-1. FASEB J. 8:1994;A338. (Abstract).
20. López-Farré A., Caramelo C., Esteban A., Alberola M.L., Millás I., Mónton M., Casado S. Effects of aspirin on platelets-neutrophil interactions. Role of nitric oxide and endothelin-1. Circulation. 91:1995;2080-2088.
21. López-Farré A., Riesco A., Digiuni E., Mosquera J.R., Caramelo C., S. de Miguel L., Millás I., de Frutos T., Cernadas M.R., Montón M., Alonso J., Casado S. Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. Circulation. 94:1996;83-87.
22. Marcus A.J. Thrombosis and inflammation as multicellular proccesses: Pathophysiology significance of transcellular metabolism. Blood. 76:1990;1903-1907.
23. Marcus A.J., Safier L.B. Thromboregulation: Multicellular modulation of platelet reactivity in hemostasis and thrombosis. FASEB J. 7:1993;516-522.
24. Metha P., Metha J.L. Effects of aspirin in arterial thrombosis: Why don't animals behave the way humans do? J. Am. Coll. Cardiol. 21:1993;511-551.
25. Mickelson J.K., Hoff P.T., Homeister J.W., Fantone J.C., Lucchesi B.R. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury. J. Am. Coll. Cardiol. 21:1993;502-510.
26. Moncada S., Palmer R.M.J., Higgs E.A. Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol. Rev. 43:1991;109-141.
27. Patterson C.E., Jin N., Packer C.S., Rhoades R.A. Activated neutrophils alter contractile properties of the human pulmonary artery. Am. J. Respir. Cell. Mol. Biol. 6:1992;260-269.
28. Rabasseda X., García-Rafanell J. Triflusal: Platelet aggregation inhibition. Drugs Today. 29:1993;1-34.
29. Riesco A., Caramelo C., Blum G., Montón M., Gallego M.J., Casado S., López-Farré A. Nitric oxide-generating system as an autocrine mechanism in human polymorphonuclear leukocytes. Biochem. J. 292:1993;791-796.
30. Rosemblum W.I., Nishimura H., Nelson G.H. L-NMMA in brain microcirculation of mice is inhibited by blockade of cyclooxygenase and by superoxide dismutase. Am. J. Physiol. 262:1992;H1343-1349.
31. 2-terminal serine of prostaglandin synthase by aspirin. J. Biol. Chem. 253:1978;3782-3784.
32. Tamaoki J., Kondo M., Takemura H., Chiyotani A., Yamawaki I., Konno K. Cyclic adenosine monophosphate-mediated release of nitric oxide from canine cultured tracheal epithelium. Am. J. Respir. Crit. Care Med. 152:1995;1325-1330.
33. Theroux P., Quimet H., McCans J., LaTour J.G., Joly P., Lévy G., Pelletier E., Juneau M., Stasiak J., de Guise P., Pelletier G.B., Rinzler D., Waters P.D. Aspirin, heparin or both to treat acute unstable angina. N. Engl. J. Med. 319:1988;1105-1111.
34. Weyrich A.S., Xin-Liang M., Lefer A.M. The role of L-arginine in ameliorating reperfusion injury after myocardial ischemia in the cat. Circulation. 86:1992;279-288.
35. Willard J.E., Lange R.A., Hillis L.D. The use of aspirin in ischemic heart disease. N. Engl. J. Med. 327:1993;175-181.
36. Xin-Liang M., Weyrich A.S., Lefer D.J., Lefer A.M. Diminished basal nitric oxide release after myocardial ischemia and reperfusion promotes neutrophil adherence to coronary endothelium. Circ. Res. 72:1993;403-412.
37. Yusuf S., Witts J., Friedman L. Overview of results of randomized clinical trials in heart disease: Unstable angina, heart failure, primary prevention with aspirin and risk factor modification. JAMA. 260:1988;2259-2263.